Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next

• In late July 2026, Replimune Group reported that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 that efficacy results from its single-arm IGNYTE trial of RP1 with nivolumab in anti-PD-1–refractory advanced melanoma are evaluable and clinically meaningful, ahead of an August 2, 2026 target FDA action date.

• The discussion highlighted how regulators weigh response durability and systemic anti-tumor activity from non-randomized data, a critical issue for gene-modified oncolytic therapies like RP1.

• With this regulatory debate over the IGNYTE trial's interpretability in focus, we'll assess how it reshapes Replimune's investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it . Find the list for free.

What Is Replimune Group's Investment Narrative?

To own Replimune today, you have to believe that gene‑modified oncolytic viruses can carve out a meaningful role in treating cancers like advanced melanoma and that RP1 can anchor a viable franchise despite ongoing losses and no revenue. The FDA advisory committee's 10–3 vote that IGNYTE's single‑arm data are "evaluable and clinically meaningful" directly affects the near‑term picture: the August 2, 2026 action date for RP1 has become the key catalyst, and the recent share price swings reflect how binary that outcome feels. At the same time, the going‑concern warning, proposal to double authorized shares to 300 million, and less than one year of cash runway keep financing and dilution risk front and center. Put together, the RP1 regulatory path, capital needs, and pipeline depth are now the core pieces of the Replimune thesis.

But this potential need for fresh capital is something investors should be very aware of.

Replimune Group's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be .

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span roughly US$1 to US$12 per share, showing how far apart private investors can be on Replimune. Set against the recent advisory committee vote and going‑concern flag, that spread underlines why it helps to compare several viewpoints before deciding how much risk around RP1's regulatory outcome you are willing to accept.

Explore 3 other fair value estimates on Replimune Group - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.